#	Pagina
attuale pagina	/open-h2020/projects/196433/index.html

Opendata, web and dolomites

DEALS

Biomarker assay development to expedite ALS experimental therapeutic advancement

Total Cost €

EC-Contrib. €

Partnership

Views

Outcomes and
results

DEALS project word cloud

Explore the words cloud of the DEALS project. It provides you a very rough idea of what is the project "DEALS" about.

proof lateral delay quick mission stem foreseen als 25 monitoring tool diseases additional symptom 2012 market soon severely symptoms disease rare practical diagnosed efficacy eradicate respiratory walking speed patients progression muscle drug onset medicinal therapies mostly received diagnosis designation developer sme clinical amyotrophic therapy successful dutch 14 progressive swallowing paper moving entrepreneurs time lack ema earlier diagnostic orphan trials slowing wasting assays detectable therapeutic characterised deals assay revenues speeding million mainly spasticity earth initial sclerosis founded perform gained speaking weakness combination economic instrumental interventions accurate feasibility final die difficulties excluding treeway benefit tests breathing biomarkers

Project "DEALS" data sheet

The following table provides information about the project.

Coordinator	TREEWAY B.V. Organization address address: SEVILLAWEG 142 city: ROTTERDAM postcode: 3047AL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.
Coordinator Country	Netherlands [NL]
Project website	http://www.treeway.nl/treeway-receive-h2020-grant-for-biomarker-feasibility-study
Total cost	71˙429 €
EC max contribution	50˙000 € (70%)
Programme	1. H2020-EU.3.1.3. (Treating and managing disease)
Code Call	H2020-SMEINST-1-2014
Funding Scheme	SME-1
Starting year	2015
Duration (year-month-day)	from 2015-05-01 to 2015-10-31

Partnership

Take a look of project's partnership.

#	participants	country	role	EC contrib. [€]
1	TREEWAY B.V. TREEWAY B.V. Organization address address: SEVILLAWEG 142 city: ROTTERDAM postcode: 3047AL website: n.a. contact info title: n.a. name: n.a. surname: n.a. function: n.a. email: n.a. telephone: n.a. fax: n.a.	NL (ROTTERDAM)	coordinator	50˙000.00

Map

Project objective

The unique Dutch SME Treeway B.V. was founded in 2012 by two highly experienced and successful entrepreneurs that both have been diagnosed with amyotrophic lateral sclerosis (ALS). It is Treeway’s mission to eradicate ALS from the face of the earth by speeding up ALS research and bringing new therapies in the market as soon as possible. Treeway already has one new therapy in clinical development, which has recently received EMA’s Orphan Medicinal Product Designation.

ALS is a rare disease that is characterised by muscle spasticity and rapidly progressive weakness due to muscle wasting. This results in difficulties in walking, moving, speaking, swallowing, and breathing. Most ALS patients die from respiratory failure within three years. ALS diagnosis currently is mainly aimed at excluding other diseases with similar symptoms. As a result there is a 9–14-month delay between symptom onset and final diagnosis of ALS. For similar reasons, there is also a lack of accurate and practical diagnostic tests for monitoring the benefit of potential therapeutic interventions for ALS. This is severely slowing down the progression of clinical drug development in this field.

As ALS drug developer, Treeway will greatly benefit from the availability of a (combination of) quick diagnostic assay(s) to be used in monitoring therapeutic efficacy in clinical trials. In addition, the ALS diagnostic tool may also proof to be instrumental for (speeding up) the initial diagnosis of the disease.

Therefore, within DEALS, Treeway will perform a mostly paper study to investigate the technical and economic feasibility of developing a quick and reliable diagnostic tool. These developments will be based on known and detectable biomarkers of the disease. Economic benefit will stem from the ability of the assays to enable earlier diagnosis and to speed up clinical drug development; per one month gained in development time for a new ALS drug, about €25 million additional revenues can be foreseen.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "DEALS" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "DEALS" are provided by the European Opendata Portal: CORDIS opendata.